Free tool
FAERS Monitor: Betamethasone Dipropionate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019141 or its brand name (Betamethasone Dipropionate, Betamethasone Dipropionate). Reports on generic versions are filed under their own applications.
Reports
5,885
Serious
4,060
69% of reports
Hospitalization
1,812
Death reported
501
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,406
- off label use641
- macular degeneration532
- nausea497
- psoriasis466
- pruritus454
- pain450
- condition aggravated410
- pain in extremity392
- headache390
- fatigue379
- rash375
- dyspnoea340
- product use in unapproved indication329
- therapeutic product effect incomplete328
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 25 |
| 2006 | 18 |
| 2007 | 24 |
| 2008 | 22 |
| 2009 | 21 |
| 2010 | 16 |
| 2011 | 41 |
| 2012 | 50 |
| 2013 | 38 |
| 2014 | 48 |
| 2015 | 87 |
| 2016 | 161 |
| 2017 | 199 |
| 2018 | 233 |
| 2019 | 334 |
| 2020 | 430 |
| 2021 | 742 |
| 2022 | 735 |
| 2023 | 760 |
| 2024 | 620 |
| 2025 | 711 |
| 2026 | 553 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,274 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 532 | 166.6 | 153.3 | 83,541 |
| therapeutic product effect incompleteSignal | 328 | 16.6 | 14.9 | 4,771 |
| psoriasisSignal | 466 | 12.8 | 11.7 | 5,068 |
| condition aggravatedSignal | 410 | 4.8 | 4.4 | 1,256 |
| pain in extremitySignal | 392 | 4.8 | 4.3 | 1,175 |
| product use in unapproved indicationSignal | 329 | 4.7 | 4.3 | 980 |
| pruritusSignal | 454 | 4.2 | 3.9 | 1,134 |
| drug ineffectiveSignal | 1,406 | 3.8 | 3.6 | 3,111 |
| rashSignal | 375 | 3.1 | 2.8 | 534 |
| painSignal | 450 | 2.6 | 2.4 | 462 |
| off label useSignal | 641 | 2.6 | 2.4 | 666 |
| nauseaSignal | 497 | 2.2 | 2.1 | 355 |
| headacheSignal | 390 | 2.2 | 2.0 | 269 |
| dyspnoeaSignal | 340 | 2.1 | 1.9 | 213 |
| fatigue | 379 | 1.7 | 1.6 | 123 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.